A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation

Ryo Aoki, Kohei Kamikado, Wataru Suda, Hiroshi Takii, Yumiko Mikami, Natsuki Suganuma, Masahira Hattori, Yasuhiro Koga

    Research output: Contribution to journalArticle

    25 Citations (Scopus)

    Abstract

    The gut microbiota is an important contributor to the worldwide prevalence of metabolic syndrome (MS), which includes obesity and diabetes. The anti-MS effects exerted by Bifidobacterium animalis ssp. lactis GCL2505 (BlaG), a highly proliferative Bifidobacterium strain in the gut, and B. longum ssp. longum JCM1217T (BloJ) were comparatively examined. BlaG treatment reduced visceral fat accumulation and improved glucose tolerance, whereas BloJ had no effect on these parameters. Gut microbial analysis revealed that BlaG exerted stronger effects on the overall bacterial structure of the gut microbiota than BloJ, including enrichment of the genus Bifidobacterium. The levels of acetate and glucagon-like peptide-1 were increased by BlaG treatment in both the gut and plasma, but not by BloJ treatment. Correlation analysis suggested that the elevation of gut acetate levels by BlaG treatment plays a pivotal role in the BlaG-induced anti-MS effects. These findings indicated that BlaG, a highly viable and proliferative probiotic, improves metabolic disorders by modulating gut microbiota, which results in the elevation of SCFAs, especially acetate.

    Original languageEnglish
    Article number43522
    JournalScientific Reports
    Volume7
    DOIs
    Publication statusPublished - 2017 Mar 2

    Fingerprint

    Bifidobacterium
    Microbiota
    Probiotics
    Acetates
    Sulfalene
    Bacterial Structures
    Glucagon-Like Peptide 1
    Intra-Abdominal Fat
    Therapeutics
    Obesity
    Glucose
    Gastrointestinal Microbiome

    ASJC Scopus subject areas

    • General

    Cite this

    A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. / Aoki, Ryo; Kamikado, Kohei; Suda, Wataru; Takii, Hiroshi; Mikami, Yumiko; Suganuma, Natsuki; Hattori, Masahira; Koga, Yasuhiro.

    In: Scientific Reports, Vol. 7, 43522, 02.03.2017.

    Research output: Contribution to journalArticle

    Aoki, Ryo ; Kamikado, Kohei ; Suda, Wataru ; Takii, Hiroshi ; Mikami, Yumiko ; Suganuma, Natsuki ; Hattori, Masahira ; Koga, Yasuhiro. / A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. In: Scientific Reports. 2017 ; Vol. 7.
    @article{aa51516ae38549a081372946aed6e598,
    title = "A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation",
    abstract = "The gut microbiota is an important contributor to the worldwide prevalence of metabolic syndrome (MS), which includes obesity and diabetes. The anti-MS effects exerted by Bifidobacterium animalis ssp. lactis GCL2505 (BlaG), a highly proliferative Bifidobacterium strain in the gut, and B. longum ssp. longum JCM1217T (BloJ) were comparatively examined. BlaG treatment reduced visceral fat accumulation and improved glucose tolerance, whereas BloJ had no effect on these parameters. Gut microbial analysis revealed that BlaG exerted stronger effects on the overall bacterial structure of the gut microbiota than BloJ, including enrichment of the genus Bifidobacterium. The levels of acetate and glucagon-like peptide-1 were increased by BlaG treatment in both the gut and plasma, but not by BloJ treatment. Correlation analysis suggested that the elevation of gut acetate levels by BlaG treatment plays a pivotal role in the BlaG-induced anti-MS effects. These findings indicated that BlaG, a highly viable and proliferative probiotic, improves metabolic disorders by modulating gut microbiota, which results in the elevation of SCFAs, especially acetate.",
    author = "Ryo Aoki and Kohei Kamikado and Wataru Suda and Hiroshi Takii and Yumiko Mikami and Natsuki Suganuma and Masahira Hattori and Yasuhiro Koga",
    year = "2017",
    month = "3",
    day = "2",
    doi = "10.1038/srep43522",
    language = "English",
    volume = "7",
    journal = "Scientific Reports",
    issn = "2045-2322",
    publisher = "Nature Publishing Group",

    }

    TY - JOUR

    T1 - A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation

    AU - Aoki, Ryo

    AU - Kamikado, Kohei

    AU - Suda, Wataru

    AU - Takii, Hiroshi

    AU - Mikami, Yumiko

    AU - Suganuma, Natsuki

    AU - Hattori, Masahira

    AU - Koga, Yasuhiro

    PY - 2017/3/2

    Y1 - 2017/3/2

    N2 - The gut microbiota is an important contributor to the worldwide prevalence of metabolic syndrome (MS), which includes obesity and diabetes. The anti-MS effects exerted by Bifidobacterium animalis ssp. lactis GCL2505 (BlaG), a highly proliferative Bifidobacterium strain in the gut, and B. longum ssp. longum JCM1217T (BloJ) were comparatively examined. BlaG treatment reduced visceral fat accumulation and improved glucose tolerance, whereas BloJ had no effect on these parameters. Gut microbial analysis revealed that BlaG exerted stronger effects on the overall bacterial structure of the gut microbiota than BloJ, including enrichment of the genus Bifidobacterium. The levels of acetate and glucagon-like peptide-1 were increased by BlaG treatment in both the gut and plasma, but not by BloJ treatment. Correlation analysis suggested that the elevation of gut acetate levels by BlaG treatment plays a pivotal role in the BlaG-induced anti-MS effects. These findings indicated that BlaG, a highly viable and proliferative probiotic, improves metabolic disorders by modulating gut microbiota, which results in the elevation of SCFAs, especially acetate.

    AB - The gut microbiota is an important contributor to the worldwide prevalence of metabolic syndrome (MS), which includes obesity and diabetes. The anti-MS effects exerted by Bifidobacterium animalis ssp. lactis GCL2505 (BlaG), a highly proliferative Bifidobacterium strain in the gut, and B. longum ssp. longum JCM1217T (BloJ) were comparatively examined. BlaG treatment reduced visceral fat accumulation and improved glucose tolerance, whereas BloJ had no effect on these parameters. Gut microbial analysis revealed that BlaG exerted stronger effects on the overall bacterial structure of the gut microbiota than BloJ, including enrichment of the genus Bifidobacterium. The levels of acetate and glucagon-like peptide-1 were increased by BlaG treatment in both the gut and plasma, but not by BloJ treatment. Correlation analysis suggested that the elevation of gut acetate levels by BlaG treatment plays a pivotal role in the BlaG-induced anti-MS effects. These findings indicated that BlaG, a highly viable and proliferative probiotic, improves metabolic disorders by modulating gut microbiota, which results in the elevation of SCFAs, especially acetate.

    UR - http://www.scopus.com/inward/record.url?scp=85014429922&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85014429922&partnerID=8YFLogxK

    U2 - 10.1038/srep43522

    DO - 10.1038/srep43522

    M3 - Article

    VL - 7

    JO - Scientific Reports

    JF - Scientific Reports

    SN - 2045-2322

    M1 - 43522

    ER -